Close Menu

NEW YORK (GenomeWeb) – 3D Signatures said today that it has signed a collaboration agreement with MDxHealth to evaluate Telo-PC, a test 3DS has developed for prostate cancer using its TeloView software platform.

Under the agreement the two companies will share the costs of conducting the study. 3DS has also granted MDxHealth an exclusive licensing option for the Telo-PC test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.